Tumor M2 pyruvate kinase - Determination in breast cancer patients receiving trastuzumab therapy

Cancer Letters

Volumn 187, Issue 1-2, 2002, Pages 223-228

  Hoopmann, Markus ^a   Warm, Mathias ^a   Mallmann, Peter ^a   Thomas, Anke ^a   Göhring, Uwe Jochen ^a   Schöndorf, Thomas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Clinical course; Trastuzumab; Tumor M2 pyruvate kinase

Indexed keywords

ANTIINFECTIVE AGENT; HORMONE; PYRUVATE KINASE; TRASTUZUMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DISEASE COURSE; DRUG BLOOD LEVEL; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PYRUVATE KINASE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0037058623     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00404-4     Document Type: Article

References (15)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
2. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udive J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
3. Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., Coombs D., Baly D., Kabbinavar F., Slamon D. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 18:1999;2241-2251.
4. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:1999;2639-2648.
5. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherpay plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N. Engl. J. Med. 344:2001;783-792.
6. Mazurek S., Grimm H., Oehmke M., Weisse G., Teigelkamp S., Eigenbrodt E. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res. 20:2000;5151-5154.
7. 2 in the regulation of phosphometabolite pools. Bannasch P., Kanduc D., Papa S., Tager J.J., Cell Growth and Oncogenesis. 1998;15-30 Birkhäuser, Basel, Switzerland.
8. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res. 20:2000;4961-4964.
9. Hardt P.D., Ngoumou B.K., Rupp J., Schnell-Kretschmer H., Kloer H.U. Tumor M2-pyruvate kinase: a promising marker in the diagnosis of gastro-intestinal cancer. Anticancer Res. 20:2000;4965-4968.
10. Oremek G.M., Eigenbrodt E., Rädle J., Zeuzem S., Seiffert U.B. Value of the serum levels of the tumor marker TuM2PK in pancreatic cancer. Anticancer Res. 17:1997;3031-3034.
11. Oremek G.M., Sapoutzis N., Kramer W., Bickeböller R., Jonas D. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma. Anticancer Res. 20:2000;5095-5098.
12. Roigas J., Schulze G., Raytarowski S., Jung K., Schnorr D., Loening S.A. Tumor M2 pyruvate kinase in plasma of patients with urological tumors. Tumour Biol. 22:2001;282-285.
13. Schneider J., Morr H., Velcovsky H.G., Weisse G., Eigenbrodt E. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect. Prev. 24:2000;531-535.
14. Schneider J., Velcovsky H.G., Morr H., Katz N., Neu K., Eigenbrodt E. Comparison of the tumor markers tumor M2-PK 21-1 CEA CYFRA NSE and SCC in the diagnosis of lung cancer. Anticancer Res. 20:2000;5053-5058.
15. Lüftner D., Mesterharm J., Akrivakis C., Geppert R., Petrides P.E., Wernecke K.D., Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res. 20:2000;5077-5082.